Core Viewpoint - Rubico Inc. has announced an agreement to acquire 100% of a Marshall Islands company that is a counterparty to a shipbuilding contract for a new medium-range oil tanker, with delivery scheduled for 2029 [1][2]. Group 1: Acquisition Details - The acquisition involves a purchase price of approximately $4.2 million for the shares of the Special Purpose Vehicle (SPV) [4]. - The transaction was approved by a special committee of independent board members, and a fairness opinion was obtained from an independent financial advisor [4]. Group 2: Financing Arrangements - The effectiveness of the shipbuilding contract is contingent upon the issuance of a customary refund guarantee and the conclusion of financing arrangements [2]. - The SPV is finalizing a lease financing agreement with ABC Financial Leasing Co., Ltd., which will cover the majority of the shipbuilding contract's price [2]. Group 3: Revenue Potential - A time charter employment has been secured with a major oil trader for the vessel, starting from its delivery for a firm duration of seven years, with an option to extend for four additional years [3]. - The total potential gross revenue backlog from this charter contract, including optional years, is estimated to be around $75 million [3]. Group 4: Company Overview - Rubico Inc. is a global provider of shipping transportation services, specializing in vessel ownership and operation [5]. - The company operates two modern, fuel-efficient Suezmax tankers and is incorporated in the Marshall Islands with executive offices in Athens, Greece [5].

Core Insights - T3 Defense Inc. has announced two senior leadership appointments to enhance execution, scalability, and long-term production reliability in the Aerospace and Defense sector [1][2] Leadership Appointments - Emil Blumer has been appointed as Chief Business Officer, responsible for growth strategy, deal flow, and market positioning, bringing over 25 years of defense industry experience [3][4] - Jordan Buchler has been appointed as Chief Executive Officer of the Manufacturing & Industrial Processing Division, focusing on expanding manufacturing throughput and standardizing processes [5][6] Experience and Responsibilities - Mr. Blumer's experience includes senior roles at Rafael Advanced Defense Systems, where he gained insights into industrial capacity and supplier readiness, which will inform T3 Defense's commercial strategy [3][4] - Mr. Buchler has over 20 years of experience in building operational systems in constrained environments, with a focus on identifying critical paths and expanding capacity in defense manufacturing [6][7] Strategic Focus - The leadership changes signal T3 Defense's commitment to enhancing the most constrained layers of the defense supply chain, operating as a federated holding company to align commercial and operational leadership [7][9] - The company aims to convert durable backlogs into repeatable production output, addressing the limitations in the industrial base that affect defense output [8][9] Company Overview - T3 Defense Inc. is a federated holding company focused on acquiring and operating mission-critical defense businesses within long-cycle national security programs, targeting areas where strategic value and execution are critical [9]

CLEARWATER, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- via IBN -- MedWell Ai, Inc, (OTCQB:MWAI) ("Company") is a portfolio company, specializing in AI-driven solutions for B2B markets in pharmaceuticals, healthcare, and wellness, is pleased to confirm the filing, after the market close, of its Quarterly Report (Form 10-Q), for the financial period, ending on December 31, 2025. The Company reported $548,315 in Revenue for its fiscal second quarter of 2025. This performance was result of a successful strategic s ...

Head Office : 4 allée de l'Arche, 92400 Courbevoie, FranceTel : + 33 (0) 1 78 15 00 00 – www.nexans.coma French Société Anonyme with a share capital of € 43,744,779 – R.C.S. Nanterre 393 525 852 – Id VAT FR 74 393 525 852 Disclosure of trading in own shares From February 16, 2026 to February 20, 2026 Issuer : Nexans Category : treasury shares Pursuant to applicable law on share buybacks, Nexans declares the following purchases of its own shares from F ...

Big Village and NeuIQ’s alliance deepens Bright Mountain’s AI-enabled decision intelligence, turning consumer insights into faster, clearer actions across brand strategy, marketing, and media execution. Boca Raton, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Bright Mountain Media, Inc. (OTCQB: BMTM) (“Bright Mountain” or the “Company”), a leading marketing services platform that empowers brands, agencies, and publishers to go further, faster, today announced a strategic partnership between Big Village, a Bright M ...

Cleanliness On-the-Go: The Honest Company’s best-selling Fragrance Free Sanitizing Wipes are now available in Lavender and Grapefruit scents and travel‑friendly pack sizes.Trusted, Clean Conscious™ Formula: Kills 99.99% of germs*, safe for hands and gentle enough for all family use and everyday routines. Sanitizing Wipes from The Honest Company, now available in Lavender and Grapefruit natural fragrance options. LOS ANGELES, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ: HNST), a personal ca ...

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Hub Group, Inc. (Nasdaq: HUBG) for potential securities law violations. Investors who have lost money in their Hub Group investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/hubg. What is this all about? Shares of Hub Group fell more than 20% in intraday trading on February 5, 2026, after the company identified an accounting error related to ...

Group 1: Kraig Biocraft Laboratories - Kraig Biocraft Laboratories' recombinant spider silk technology has gained significant visibility by being featured on the cover of National Geographic's March 2026 issue, which could lead to increased investor interest [2][4] - The company is set to deploy approximately one million proprietary silkworm eggs across three facilities in Vietnam, aiming for a production target of up to 10 metric tons of cocoons per month starting in March 2026 [5] - Scientific validation published in the Proceedings of the National Academy of Sciences confirms that Kraig's fibers are tougher than conventional silk and comparable to native spider dragline silk [5] - If successful, Kraig could become the second company to achieve sustained commercial production from a transgenic animal platform, a milestone previously associated with ATryn [6] - Investors are closely monitoring for initial deliveries to global brand partners in luxury fashion and performance sportswear, which could transition Kraig from a research-focused entity to a specialty materials platform [8] Group 2: Gilead Sciences and Arcellx - Gilead Sciences has announced a definitive agreement to acquire Arcellx for $115 per share in cash, plus a $5 contingent value right, representing an implied equity value of approximately $7.8 billion [9] - The acquisition provides Gilead with full control of anitocabtagene autoleucel, a CAR T-cell therapy for multiple myeloma, with the FDA accepting the BLA and a PDUFA action date set for December 23, 2026 [10] - Gilead's CEO emphasized the potential of anito-cel to become a foundational treatment for multiple myeloma and its importance in enhancing Gilead's oncology and inflammation capabilities [11] Group 3: ImmunityBio - ImmunityBio reported approximately $113 million in net product revenue for ANKTIVA in 2025, reflecting a 700% year-over-year growth [13] - The company also experienced a 750% increase in unit sales volume and expanded regulatory authorization across 33 countries [13] - ImmunityBio is positioning ANKTIVA as a backbone immunotherapy platform with ongoing randomized trials and long-term patent protection extending beyond 2035 [15] Group 4: Getty Images and Shutterstock - Getty Images and Shutterstock received unconditional antitrust clearance from the U.S. Department of Justice for their proposed merger, which aims to strengthen their financial foundation and competitive positioning in the visual content market [16][17]

Core Viewpoint - The Ultragenyx Pharmaceutical Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding the efficacy of their drug setrusumab for treating Osteogenesis Imperfecta [1][3]. Company Overview - Ultragenyx is a biopharmaceutical company focused on developing treatments for rare and ultra-rare genetic diseases [2]. Allegations of the Lawsuit - The lawsuit claims that Ultragenyx misrepresented the reliability of information regarding setrusumab's effects on patients and downplayed the risks associated with the Phase III Orbit study, which ultimately failed to show statistically significant results [3]. - On July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study did not achieve statistical significance for its second interim analysis, leading to a stock price drop of over 25% [4]. - Following a December 29, 2025 announcement that both the Phase III Orbit and Cosmic studies failed to meet primary endpoints, Ultragenyx's stock fell more than 42% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Ultragenyx common stock during the class period to seek appointment as lead plaintiff, representing the interests of the class [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone, and a total of $8.4 billion over the past five years [7].

Core Economic Terms - Jupiter Neurosciences, Inc. has deferred the commencement of repayment for its financing to April 1, 2026, while the core economic terms of the $6.0 million financing remain unchanged [1][2][8] - The amendment does not introduce new pricing provisions, reset features, or additional financing commitments, focusing solely on installment timing and application mechanics [2] Strategic Alignment - The amendment reflects a strategic decision between Jupiter and Yorkville, demonstrating Yorkville's commitment to Jupiter's long-term strategy by adjusting installment timing without altering pricing or other economic terms [3] - This alignment allows the company to focus on advancing its Phase II Parkinson's program and scaling its product Nugevia™, which is generating commercial cash flow [3] Commercial Performance - Jupiter's strategy combines clinical development with active commercial revenue generation, with Nugevia™ showing repeat purchase activity of approximately 25% and product return rates of about 3% [3] - The company believes that early commercial validation, along with continued clinical progress, strengthens its capital profile and differentiates it from biotechnology peers reliant solely on capital markets funding [3] Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on therapies for neuroinflammation and central nervous system disorders, with its lead clinical program in a Phase IIa trial for Parkinson's disease [5] - The company is also commercializing Nugevia™, a consumer product based on its patented JOTROL™ technology platform designed to enhance resveratrol bioavailability [5]